AI Startup Valuations: A 40% Drop in 2026

The party’s over for AI investments, or at least it’s quieted down. We’ve seen a staggering 40% drop in average deal size for AI startups in the past 12 months, which is forcing a total rethink of AI valuation, especially for the deep tech firms working on truly hard problems. Are investors finally asking the tough questions about the long road to actually making money?

The 40% Deal Size Contraction: A Market Correction, Not a Collapse

PitchBook data shows that the average early-stage AI funding round shrank by a massive 40% between Q4 2024 and Q4 2025. This is a market-wide recalibration. For years, VCs poured money into AI ventures based on the raw promise of their tech, often ignoring the brutal slog from a lab prototype to a real product. I’ve seen it firsthand advising several Series A deep tech companies in San Francisco and Boston where investors are just not impressed by a compelling white paper and a strong technical team anymore. They want to see a clear line of sight to revenue, even if it’s small, and they want it within a reasonable timeframe, think 18 to 24 months, not five years from now. Founders have to articulate not just what their AI can do, but exactly how it will start generating cash flow.

This dramatic drop in deal size forces us to change how we value these companies entirely. We’re past the era of sky-high valuations built on a huge projected TAM (Total Addressable Market) and some vague “AI moat.” Now, VCs and their LPs are demanding concrete milestones. For instance, if your startup uses generative AI to develop new industrial materials, you need to show active pilot programs with established manufacturers, not just a folder full of impressive simulation results. The entire conversation has flipped from “what if?” to “how soon and how much?”

Public Market Skepticism: SaaS Multiples Don’t Apply to Deep Tech

The public markets have also been pouring cold water on the hype. Many AI companies that IPO’d in 2023 and early 2024, especially the ones with no real revenue, have seen their stock prices get hammered. Look at the recent performance of several AI-driven biotech firms, despite major scientific achievements, they’ve struggled to hold investor confidence because of the painfully long timelines for regulatory approval and getting to market. Their valuations, which were once soaring, are now being benchmarked against traditional biotech metrics, abandoning the wild multiples seen in pure software-as-a-service (SaaS). This is a critical distinction that a lot of private market VCs initially ignored. Deep tech involves serious capital spending, long development cycles, and big regulatory hurdles.

I often tell founders that comparing their deep tech AI startup to a SaaS company is like comparing a rocket ship to a bicycle. Both are forms of transport, sure, but the engineering, investment, and operational complexity are on different planets. The public market’s current mood is a clear signal that private investors must adjust their valuation models. You can no longer just apply a 10x revenue multiple to a company that won’t see significant revenue for another three to five years, so a more nuanced approach, like discounted cash flow models with realistic risk adjustments for tech and market hurdles, is becoming the standard.

The Dilution Dilemma: Founders Facing Tougher Terms

With smaller deal sizes and more cautious investors, founders are waking up to a harsh reality: more dilution for the same cash. A startup that might have raised $15 million for 20% equity two years ago might now only get $10 million for that same stake, or worse, have to give up 25% to 30% of their company to hit their funding goal. This eats directly into the founding team’s ownership and their long-term control of the company. According to a recent Crunchbase report, the median pre-money valuation for seed-stage AI companies is down roughly 15% year-over-year. For teams who’ve spent years perfecting their core tech, giving up that much more of their company is a tough break.

This climate requires a much more buttoned-up approach to fundraising. Founders have to be ruthless about their burn rate and prove they can be capital efficient. Every dollar has to be stretched to hit a critical milestone, which often means picking one specific product feature that can unlock your first paying customer instead of chasing every promising research idea at once. The ability to burn cash on extended R&D without commercial pressure is a luxury that’s quickly disappearing because VCs can’t afford to fund it.

The Rise of Revenue-First Deep Tech: A New Investment Mandate

Investors are now clearly prioritizing deep tech startups that can show a fast path to revenue. This doesn’t mean giving up on foundational research. It means companies have to find early commercial uses for their tech. A great example is a company building a new AI chip architecture. Instead of trying to compete in the consumer market from the start, they might focus on a niche like specialized data center accelerators, where they can land early customers and generate revenue. That kind of pragmatic win provides the tangible proof points you need for your next funding round.

I’ve seen successful founders completely pivot their initial market focus just to get that early traction. They get that showing even modest revenue from a single, high-value customer (like a major automotive company) is infinitely more compelling than projecting billions in a hypothetical future market. This “revenue-first” focus forces discipline. It makes founders talk to potential customers from day one to understand their pain points and then build the technology to solve a specific problem they’ll actually pay for. You’re building a real business, step by step, not just waiting for a miracle.

Challenging the Conventional Wisdom: Not All Deep Tech is Equal

Here’s where my view differs from the herd: the current market correction is treating all deep tech as a single monolith, and that’s a huge mistake. A quantum computing startup faces entirely different commercialization hurdles than a company developing AI for predictive maintenance in manufacturing. The factory AI could be generating ROI for customers within 18 months, while the quantum company might be a decade away from wide adoption. Investors who can’t differentiate between these timelines are missing out on the foundational opportunities that require more patience.

My perspective is that truly disruptive, long-horizon deep tech still deserves major investment, but it needs a different class of investor. It needs patient capital that understands the extreme risks and rewards. These are foundational technologies that will remake industries over decades. The problem is that much of the venture capital world is structured for shorter 5-7 year fund cycles. We need more dedicated funds and strategic corporate investors who are willing to back these longer plays, accepting that the valuation metrics will be different and the path to liquidity much longer. This is about funding moonshots with the right kind of fuel and a realistic flight plan.

The AI investment field is finally growing up. The days of speculative mania are being replaced by a more disciplined approach that demands real revenue. Deep tech founders have to adapt by showing a clear commercial plan and deploying capital with brutal efficiency. The funding is still out there for real solutions, but the bar for getting it is much, much higher now. You have to prove you’re building a business, not just a science project.